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Background: Echocardiographic upper normal limits of both main pulmonary artery (MPA) diameters (MPA-d) and
ratio of MPA to aortic root diameter (MPA-r) are not defined in healthy adults. Accordingly, frequency of MPA
dilatation based on echocardiography remains to be assessed in adults with Marfan syndrome (MFS).
Methods: We enrolled 123 normal adults (72 men, 52 women aged 42 ± 14 years) and 98 patients with MFS (42 men,
56 women aged 39 ± 14 years) in a retrospective cross-sectional observational controlled study in four tertiary care
centers. We defined outcome measures including upper normal limits of MPA-d and MPA-r as 95 quantile of normal
persons, MPA dilatation as diameters > upper normal limits, MPA aneurysm as diameters >4 cm, and indication for
surgery as MPA diameters >6 cm.
Results: MPA diameters revealed normal distribution without correlation to age, sex, body weight, body height, body
mass index and body surface area. The upper normal limit was 2.6 cm (95% confidence interval (CI) =2.44-2.76 cm) for
MPA-d, and 1.05 (95% CI = .86–1.24) for MPA-r. MPA dilatation presented in 6 normal persons (4.9%) and in 68 MFS
patients (69.4%; P < .001), MPA aneurysm presented only in MFS (15 patients; 15.3%; P < .001), and no patient required
surgery. Mean MPA-r were increased in MFS (P < .001), but ratios >1.05 were equally frequent in 7 normal persons (5%)
and in 8 MFS patients (10.5%; P = .161). MPA-r related to aortic root diameters (P = .042), reduced left ventricular ejection
fraction (P = .006), and increased pulmonary artery systolic pressures (P = .040). No clinical manifestations of MFS and no
FBN1 mutation characteristics related to MPA diameters.
Conclusions: We established 2.6 cm for MPA-d and 1.05 for MPA-r as upper normal limits. MFS exhibits a high
prevalence of MPA dilatation and aneurysm. However, patients may require MPA surgery only in scarce circumstances,
most likely because formation of marked MPA aneurysm may require LV dysfunction and increased PASP.
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The old Ghent nosology considered dilatation of the
main pulmonary artery (MPA) as a diagnostic criterion
of Marfan syndrome (MFS) [1] but data on the preva-
lence of MPA dilatation or aneurysm remained both
scarce and conflicting in MFS [2-5]. Most likely, little at-
tention has been paid to MPA because cardiovascular
complications of MFS usually result only from rupture
or dissection of the aortic root [6] or from ventricular
arrhythmia [7,8]. Moreover, cardiovascular criteria of
MFS are usually assessed with transthoracic echocardi-
ography, but in adults upper normal limits of diameters
of the MPA (MPA-d) remain to be defined on echocar-
diography [9]. As a consequence, there is no current
data on the echocardiographic prevalence of MPA dilata-
tion in MFS patients, and for this reason the revised
Ghent nosology removed MPA dilatation from the list of
diagnostic criteria [9]. Some case reports highlight that
MPA dilatation may lead to severe complications in MFS
[10], and current magnetic resonance imaging (MRI) and
computed tomography (CT) studies suggest that path-
ology of the MPA is frequent in MFS [3-5,11,12]. Hence,
echocardiographic examination of the MPA may be im-
portant in the evaluation of adults with MFS to further
elucidate the diagnostic and prognostic implications of
MPA dilatation.
Dilatation of the MPA is present with MPA-d above
upper normal limits, where CT and MRI studies identi-
fied diameters between 2.8 cm and 3.2 cm as upper
limits [4,13-15]. Moreover, the MPA ratio (MPA-r) is de-
fined as a ratio of MPA-d to aortic root diameter [14].
Usually, the diameter of MPA equals the size of the
proximal aorta, and hence CT or MRI studies of pul-
monary hypertension (PH) identify ratios >1 as a marker
of MPA dilatation [14,16-19]. The largest study of refer-
ence values of MPA is the Framingham study which
used non-contrast cardiac CT in 706 normal adults. This
study established 2.9 cm in men and 2.7 cm in women
as sex-specific normative reference values for MPA-d
and 0.9 for MPA-r [14]. Aneurysms of MPA are defined
with MPA-d >4 cm [20,21]. Such aneurysms are re-
ported in 1 of 14,000 autopsies [22]. Criteria for surgery
of MPA aneurysms are not firmly established, but
surgeons agree to operate upon in most patients with
symptomatic MPA aneurysms or in aneurysms with
MPA-d >6 cm [20,21,23].
Normative MPA-d and MRA-r values on CT and MRI
do not apply to transthoracic echocardiography for vari-
ous reasons. First, echocardiographic MPA-d and aortic
root diameters are measured at other sites of the vessel
than on CT or MRI, which may infer substantial differ-
ences of measurements because of the asymmetric anat-
omy of both MPA and the aortic root [2,5,24]. Second,
measurements on CT and MRI are usually obtainedas outer diameters of the vessel rather than with the
leading-edge method [24-26]. Third, compared to CT
and MRI, transthoracic echocardiography has inherent
limits such as measurement of MPA-d only in parallel
and not perpendicular to the direction of the scan plane
[27], inadequate images due to chest wall deformities in
MFS patients which is reported in 5 to 23 percent [28],
and the difficulty to obtain adequate imaging of the pul-
monary root.
MPA aneurysms usually occur in the setting of PH,
and they have been reported in PH group 1 [29] includ-
ing PH related to congenital heart disease [30], where
patent ductus arteriosus is the most frequently reported
underlying pathology of the MPA aneurysms [31,32], PH
group 2, including acquired heart valve disease [20], and
PH group 3 including chronic obstructive pulmonary
disease (COPD) [33]. Some MPA aneurysms arise in the
absence of PH, and they may have a more benign prog-
nosis than high pressure MPA aneurysms [30,32]. These
low pressure MPA aneurysms may arise from pulmonary
valve stenosis [20,34], vasculitis such as Behcet’s disease
[35] or giant cell arteritis [36], infections such as tuber-
culosis [37], syphilis [38,39] and septic emboli [22],
extravascular [40] or endovascular trauma [31,41], or de-
generative diseases including atherosclerosis [42] and
media degeneration [43]. Some “idiopathic” MPA aneu-
rysms may form without any of these causes [20,23,44].
MPA aneurysms are usually asymptomatic but they
may lead to symptoms from right heart failure secondary
to pulmonary regurgitation or from compression of the
trachea or bronchi, or from pulmonary emboli, which
may form in the enlarged MPA [20,31]. MPA dissection
is a rare complication of marked MPA aneurysm [21],
which is often fatal because it leads to rupture rather
than to formation of a re-entry [45].
MPA aneurysms may develop in patients with herit-
able connective tissue diseases such as Loeys-Dietz syn-
drome [46,47], and arterial tortuosity syndrome [48], but
it is most typically observed in MFS [2-5,49-54]. MFS
is an autosomal dominantly inherited disease with a
phenotype that involves multiple organ systems and is
caused by mutations in the gene coding for fibrillin-1,
FBN1. MPA dilatation and aneurysm develop in the
absence of common risk factors such as PH, or pulmon-
ary valve or artery stenosis [1]. Instead, it is likely that
MPA dilatation and aneurysm develop as a consequence
of the weakness of the connective tissue with degener-
ation of the media layer of the pulmonary vessel simi-
lar to the process in the aortic root. As had been
pointed out previously, the common embryonic origin
of MPA and the aortic root may in part explain the com-
mon involvement of both vessels in pathologic processes
[3,55], where this common involvement is also the reason
why MFS is considered an absolute contraindication for
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operation [56,57].
We performed this retrospective cross-sectional obser-
vational controlled study with the goal to identify upper
normal limits of MPA-d on echocardiography. Moreover,
we intended to use these upper normal limits to assess
frequency of MPA dilatation, MPA aneurysm, and the
need for MPA surgery in adult MFS patients. Finally, we
aimed to identify risk factors of MPA dilatation in MFS




The study was approved by the Hamburg and the Ghent
ethics committee and it was carried out in compliance
with the Helsinki Declaration, where patients gave con-
sent to the inclusion into retrospective pseudonymized
data analysis. First, we recruited normal individuals
aged ≥16 years, with normal results on echocardiog-
raphy including normal pulmonary artery systolic pressure
(PASP) as estimated <30 mmHg from the tricuspid jet vel-
ocity obtained during echocardiographic evaluation [58],
to establish normal echocardiographic MPA-d. These indi-
viduals underwent cardiovascular evaluation as check-up
examinations, as examinations prior to non-cardiovascular
operations, or for documentation of cardiovascular health
prior to the initiation of medications with potential side-
effects on the cardiovascular system. We excluded persons
with a history or current symptoms of cardiovascular dis-
ease, lung disease such as COPD, pulmonary embolism, or
cardiovascular risk factors comprising diabetes mellitus,
chronic arterial hypertension, or with a long-standing his-
tory of smoking or current smoking. In this way we identi-
fied 73 persons from the University Hamburg-Eppendorf,
18 persons from the Ghent University, 11 persons from
the University of Münster, and 21 persons from the
University of Lübeck. Thus, echocardiographic record-
ings of a total of 123 normal persons comprising 72 men
and 52 women at a mean age of 42 ± 14 years (range 16–
77 years) were available for uniform assessment of nor-
mal MPA-d and MPA-r.
Second, we identified a total of 167 adult inhabitants
of the Hamburg metropolitan area [59] with a causative
FBN1 gene mutation, who fulfilled diagnostic criteria
of MFS according to the current Ghent nosology [9].
Of these 167 patients, we excluded 86 because original
echocardiographic recordings were not available, and 5
because we did not perform standardized MPA measure-
ments. Of these remaining 76 patients we excluded 4
other patients, because MPA measurements were tech-
nically inadequate (5.2%). In addition, 26 patients were
recruited in Ghent, who were recruited according to the
same criteria as in Hamburg [9]. Thus, we identified atotal of 98 patients with MFS for this study including
42 men and 56 women at a mean age of 39 ± 14 years
(range 14–79 years).
Clinical variables
We obtained age, body weight, body height, at the time
of echocardiography, and we calculated body mass index
(BMI) and body surface area (BSA) with the formula of
Du Bois [60]. We re-evaluated standard 2-dimensional
transthoracic echocardiographic recordings to assess left
ventricular (LV) ejection fractions (LVEF) using Simpson’s
rule [61], and 2-D-targeted M-mode for LV end-systolic
(LVESD) and LV end-diastolic diameters (LVEDD) with
normalization to BSA, all assessed according to current
guidelines [61]. We measured aortic root diameters in the
parasternal long-axis view at the level of the aortic sinuses
at end-diastole using the leading-edge method as suggested
recently (Figure 1, left panel) [62,63] with calculation
of Z-scores according to the revised formula of Devereux
et al. [64] where we calculated BSA according to Du Bois
[60] (Tables 1 and 2).
MPA measurements and definitions
We measured MPA-d in the parasternal short-axis view
at the level of the maximum diameter above the level
of the pulmonary root at end-diastole [55] using the
leading-edge method (Figure 1, right panel) [65], and
we calculated the MPA-r as the ratio of the MPA-d and
the aortic root diameter as measured at the level of the
aortic sinuses (Figure 1, left panel) [14]. We defined
upper normal limits of MPA-d and MPA-r as the 95
quantile of measurements of normal persons. Based
on MPA measurements, we defined MPA dilatation
as diameters > upper normal limits, MPA aneurysm as
diameters >4 cm [20,21], and indication for surgery as
MPA-d >6 cm (Table 3) [20,21].
MFS-related variables
We considered a family history of MFS in patients with
a parent, child or sib who fulfilled diagnostic criteria of
MFS. We established ectopia lentis with any unilateral
or bilateral displacement of the lenses as documented
on slit-lamp examination under full pupillary dilatation
[9], or after operation for this entity. We documented
pneumothorax with spontaneous pneumothorax on med-
ical records [59], dural ectasia with lumbosacral dural
ectasia according to the criteria of Habermann [66,67],
striae distensae with striae that were not associated
with pronounced weight changes or pregnancy, or with
uncommon location such as the mid back, lumbar re-
gion, the upper arm, axillary region or thigh as docu-
mented during physical examination [9]. We diagnosed
myopia with > −3 diopters on refractometry during oph-
thalmic examination or with > −3 diopters documented
Figure 1 We used 2-dimensional echocardiography to measure both, aortic root diameters and main pulmonary artery (MPA) diameters.
We performed all measurements at end-diastole perpendicular to the long axis of the vessel using the leading-edge method. We assessed aortic root
diameters in the parasternal long-axis view at the level of the aortic sinuses (left panel) [62], and we measured MPA diameters in the parasternal
short-axis view at the level of the maximum diameter above the root of the pulmonary artery (right panel).
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posterior or anterior late systolic prolapse on M-mode or
on 2-dimensional echocardiography from parasternal long
axis views and apical 4-chamber views as leaflet dis-
placement >2 mm [68]. We documented a systemic
score ≥7 points as defined by revised Ghent criteria [9],
where we displayed the score separately for skeletal fea-
tures comprising the wrist sign, the thumb sign, pectus car-
inatum, pectus excavatum, chest asymmetry, hindfoot
deformity, plain pes planus, protrusio acetabuli, reduced
upper segment/lower segment ratio, increased arm/height
ratio, scoliosis or thoracolumbar kyphosis, reduced elbowTable 1 Baseline characteristics
Variable Normal persons Marfan patients P1
(N = 123) (N = 98)
Male gender 72 (59%) 42 (43%) .022
Age (years) 42 ± 14 (16–77 ) 39 ± 14 (14–79) .113
Body weight (kg) 75 ± 14 (50–128) 74 ± 14 (45–115) .398
Body height (m) 1.76 ± .1 (1.51–1.99) 1.85 ± .1 (1.58–2.10) <.001
Body mass index (kg/m2) 24.2 ± 3.5 (16.3–39.9) 21.5 ± 3.6 (15.2–30.8) <.001
Body surface area
(DuBois; m2)
1.9 ± .21 (1.51–2.43) 1.96 ± .21 (1.51–2.51) .040
Aortic root diameter (cm)2 3 ± .5 (1.9–4.2) 4.0 ± .7 (2–5.5) <.001
Z-score of aortic root
diameter
-.8 ± 1.6 (−6.2–1.9) 2.9 ± 2.3 (−4.4–7.4) <.001
LV ejection fraction (%) 64 ± 6 (55–76) 55 ± 12 (21–78) <.001
LVESD (mm/m2) 16 ± 3 (9–24) 18 ± 4 (10–36) .005
LVEDD (mm/m2) 26 ± 3 (18–32) 27 ± 5 (20–48) .009
Indexed left atrial diameter
(mm/m2)
19 ± 3 (13–27) 19 ± 5 (8–32) .339
LV identifies left ventricle; LVEDD, indexed left ventricular end-diastolic diameter;
LVESD, indexed left ventricular end-systolic diameter, and MPA ratio, ratio of
main pulmonary artery diameter/aortic root diameter. 1Fisher’s exact test for
nominal and categorical data and the Mann–Whitney test for continuous
data. 2We obtained aortic root diameters in 103 normal persons and in 76
patients with Marfan syndrome.extension, and facial features as the skeletal score, and
pneumothorax, skin striae, myopia > −3 diopters, and mi-
tral valve prolapse as the non-skeletal score (Table 4) [69].
Molecular analysis
We amplified all 65 coding exons and intronic flanking
splice-sites of FBN1 (NM_000138.4) with polymerase
chain reaction (PCR) from genomic deoxyribonucleic acid
with previously published primers [70]. Subsequently we
purified PCR products and sequenced with a Genetic
Analyser (ABI 3130XL, Applied Biosystems Inc., Foster
City, CA, USA). We detected gross deletions/duplications
in the FBN1 gene with multiplex ligation-dependent probe
amplification (MLPA; SALSA® MLPA® kit, probemix P065
and P066, MRC Holland, Amsterdam, Netherlands). All
FBN1 gene nucleotide changes fulfilled ≥1 Ghent criteria
of causality as defined by the current Ghent nosology [9].
FBN1 mutation characteristics
To assess FBN1 mutation characteristics we compared
both premature truncation codon-mutations, and spli-
cing mutations versus all other mutations. In mutations
with elimination or creation of a cysteine, with location
in a calcium binding calcium binding epidermal growth
factor-like (cbEGF) domain, or in a latent transforming-
growth-factor beta–binding protein-like (LTBP) domain,
or in exons 24–32, we first compared all mutations with
the respective characteristic versus all other exon muta-
tions, and second only missense mutations with the re-
spective characteristic versus all other missense mutations
(Table 4) [69,71].
Data analysis
We expressed quantitative data as means ± standard devi-
ation (range), and qualitative data as numbers (percentage).
We compared qualitative data with the Fisher’s exact
Table 2 Correlation r of variables with the diameter of the main pulmonary artery (cm)
Product–moment correlation coefficient r (P-value)1
Normal persons Marfan patients
Variable All2 Male Female All Male Female
(N = 123) (N = 72) (N = 51) (N = 98) (N = 42) (N = 56)
Age (years) -.095 (.296) -.01 (.929) -.2 (.159) .203 (.045) .279 (.074) .152 (.262)
Body weight (kg) .172 (.057) .013 (.913) .293 (.037) .115 (.261) .125 (.429) .133 (.327)
Body height (m) .09 (.319) .049 (.681) .145 (.311) .093 (.362) .108 (.498) .130 (.340)
Body mass index (kg/m2) .141 (.121) -.036 (.766) .269 (.056) .076 (.459) .096 (.543) .062 (.648)
Body surface area (DuBois; m2) .149 (.099) .032 (.789) .262 (.063) .120 (.240) .142 (.369) .146 (.282)
1P-value for rho. 2The mean MPA diameters were 2.07 cm in normal males versus 2.05 cm in normal females (P = .747).
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(Tables 1 and 3). We employed the Shapiro-Wilk W
test for normal data and the qnorm plot (Q-Q plot;
Figure 2) to test for normal distribution of MPA-d [72],
and we assessed the correlation of variables with MPA-d
by means of the product–moment correlation coefficient r
(Table 2). We used the quantile regression to estimate the
95-quantile and its 95%-confidence interval. We used the
bootstrap technique to get robust estimation of the stand-
ard errors. Finally, we examined the relationship of clinical
and molecular variables with MPA-d as dependent vari-
able with linear regression analysis (Table 4). We consid-
ered P-values < .05 as significant. We used SPSS software
(SPSS for Windows, Release 17.0, SPSS Inc. 1993 to 2007,
Chicago, Illinois) and Stata 13 (Stata Statistical Software,
Release 13; College Station, TX: StataCorp LP) for statis-
tical analyses.
Results
Baseline characteristics revealed less females (P = .022),
smaller body-height, BSA (P = .040), aortic root diameters,
aortic Z-scores (all P < .001), indexed LVESD (P = .005) andTable 3 Two-dimensional echocardiographic findings of
the main pulmonary artery (MPA)
Variable Normal persons Marfan patients P1
(N = 123) (N = 98)
MPA diameter (cm) 2.1 ± .3 (1.1–3.1) 3.1 ± .7 (1.9–4.7) <.001
MPA dilatation
(diameter > 2.6 cm)
6 (4.9%) 68 (69.4%) <.001
MPA aneurysm
(diameter > 4.0 cm)
0 15 (15.3%) <.001
MPA diameter > 6.0 cm 0 0
MPA ratio2 .7 ± .19 (.3–1.2) .8 ± .21 (.5–1.5) .001
MPA ratio > 1.052 6 (5.8%) 8 (10.5%) .161
LV identifies left ventricular; LVEDD, indexed left ventricular end-diastolic diameter;
LVESD, indexed left ventricular end-systolic diameter, and MPA ratio, ratio of main
pulmonary artery diameter/aortic root diameter. 1Fisher’s exact test for nominal
and categorical data and the Mann–Whitney test for continuous data. 2We
obtained aortic root diameters in 103 normal persons and in 76 patients with
Marfan syndrome.indexed LVEDD (P = .009) and higher BMI and LVEF
(both P < .001) in normal adults than in MFS (Table 1).
MPA-d revealed normal distribution (Figure 2; P = .133)
without correlation to age, body weight, body height, BMI
and BSA both in normal adults and in MFS and with
equal distribution of MPA diameters in men and women
(P = .747; Table 2). The mean MPA-d in normal adults
was 2.1 cm (95% confidence interval (CI) = 2.00–2.12 cm),
and the upper normal limit of MPA-d was 2.6 cm (95%
CI = 2.44-2.76 cm). The mean MPA-r in normal adults
was .70 (95% CI = .67 – .74), and the upper limit of normal
MPA-r was 1.05 (95% CI = .86– 1.24).
With 2.1 ± .3 versus 3.1 ± .7 (P < .001), and with .71 ± .19
versus .8 ± .31 (P < .001), both MPA-d and MPA-r were
smaller in normal persons than in MFS. MPA dilatation
was present in 6 normal persons (4.9%) and in 68 MFS
(69.4%; P < .001), MPA aneurysm was diagnosed only in
MFS (15 patients; 15.3%; P < .001; Figure 3, upper panel),
but no patient required surgery of MPA aneurysm. Using
our threshold >1.05, MPA-r were increased in 6 normal
persons (5.8%) and in 8 MFS patients (10.5%; P = .161;
Table 3; Figure 3, lower panel).
Finally, linear regression analysis identified a rela-
tionship of increased MPA-d with increased aortic
root diameters (regression coefficient (b) = .308; 95%
CI .011–.604; P = .042), with reduced LVEF (b = −.021; 95%
CI = −.036–.006; P = .006), with increased indexed LVEDD
(b = .043; 95% CI = −.007–.079; P = .021), and with in-
creased PASP (b = .023; 95% CI = .001–.045; P = .040).
Conversely, no clinical manifestation of MFS, and no
FBN1 mutation characteristic related to MPA-d (Table 4).
Discussion
Our study yielded five major results. First, we identified
echocardiographic MPA-d >2.6 cm as upper normal
limit of normal adults independent of age, sex, body
height, body weight, BMI and BSA. Second, adults with
MFS exhibited MPA dilatation in 69.4%, and MPA
aneurysm in 15.3%, where no patient fulfilled criteria
for surgical intervention. Third, MPA-r were increased in







Aortic root dilatation -.118 -.491–.225 .531
Previous aortic root surgery -.054 -.449–.342 .787
Aortic root diameter (cm) .308 .011–.604 .042
Z-score of aortic root diameter .035 -.051–.122 .414
LV ejection fraction (%) -.021 -.036–.006 .006
LVESD (mm/m2) .024 . -.018–.065 .258
LVEDD (mm/m2) .043 -.007–.079 .021
PASP (mmHg)2 .023 .001–.045 .040
Family history of Marfan .132 -.217–.482 .452
Ectopia lentis -.183 -.531–.165 .298
Pneumothorax -.133 -.617–.351 .585
Dural ectasia (Habermann) .095 -.254–.443 .590
Striae distensae -.021 -.331–.373 .906
Myopia > −3 diopters -.294 -.691–.102 .143
Mitral valve prolapse .224 -.427–-.020 .081
Systemic score≥ 7 points -.026 -.415–.364 .895
- Total systemic score points -.010 -.076–.054 .764
- Skeletal score points -.030 -.113–.053 .470
- Non-skeletal score points .033 -.095–.161 .610
FBN1 mutation characteristics
PTC mutations -.150 -.550–.249 .455
Splicing mutations .208 -.422–.837 .513
Any mutation affecting Cys .027 -.359–.412 .890
Missense affecting Cys -.026 -.536–.484 .919
Any mutation in cbEGF -.133 -.365–.262 .589
Missense in cbEGF -.021 -.564–.606 .943
Any mutation in LTBP-bd -.540 −1.240–.160 .128
Missense mutation in LTBP-bd .018 −1.106–1.142 .974
Any mutation in exons 24–32 -.135 -.643–.373 .597
Missense in exons 24–32 -.014 -.654–.629 .965
cbEGF indetifies calcium-binding epidermal growth factor-like domain; coefficient,
regression coefficient; Cys, cysteine; LV, left ventricular; LVEDD, indexed left
ventricular end-diastolic diameter, LVESD, indexed left ventricular end-systolic
diameter, LTBP-bd, latent TGF-beta-binding domain; missense, missense mutation;
N, number; PASP, pulmonary artery systolic pressure; and PTC, premature
termination codon. 1We analyzed on those 72 patients, whom we recruited in
Hamburg. 2Linear regression analysis. 2PASP measurements were 22 ± 12 mmHg
(range 6 – 49 mmHg).
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was identified as the upper normal limit. Fourth, MPA-d
are similar in normal persons and MFS and may thus
not be useful as diagnostic markers of MPA dilatation
in MFS. Finally, MPA-d increased with PASP, aortic
root diameters, reduced LVEF, dilated LVEDD but MPA-d
did not relate to manifestations of MFS or to FBN1 muta-
tion characteristics.
In normal adults, upper limits of MPA-d were only
defined on CT and MRI, where limits ranged between2.8 cm [4], 2.96 cm [13], 3.01 cm [14], and 3.24 cm
[15]. Our echocardiographic limit of 2.6 cm was slightly
lower most likely because measurements on tomo-
graphic studies are usually obtained as outer diameters
of a vessel rather than with the leading-edge method
[25,26]. Our threshold may also be because some stud-
ies did not exclude PH [4,14,18]. Moreover, echocardi-
ography measures MPA-d at other sites than on CT or
MRI [2]. Most importantly, upper limits of MPA-d
were defined differently as 90th percentile [14], as 95th
percentile [13], or as diameters 0.5 mm above the max-
imum diameter [4]. One study used the maximum di-
ameters measured in normal persons as upper normal
limit of MPA-d [15]. Similarly, De Backer et al. identi-
fied 2.3 cm as cut-off of normal limit MPA-d on echo-
cardiography, but they employed receiver operating
characteristic curve analysis to separate normal persons
from MFS rather than that they defined upper normal
limits of MPA-d [2].
Using 2.6 cm as threshold we identified a high preva-
lence of MPA dilatation in MFS. One MRI study of 86
MFS patients listed different cut off values for MPA di-
ameters [3], and used various methods to assess MPA
dilatation: According to the old Ghent criteria for as-
sessment of MPA dilatation [1], where a nomogram of
the aorta made by Roman et al. [62] was employed to
assess MPA dilatation, none of the patients were found
to have dilatation of the MPA, and only seven patients
had dilatation of the root of the pulmonary artery. Con-
versely, when using the cut off ≥3.0 cm as proposed
by Bozlar et al. [13], the same authors found that 54%
of MFS patients had MPA dilatation. Another study
identified 76% of 50 MFS patients using 2.8 cm at the
level of the bifurcation as threshold for MPA dilatation
[4]. Interestingly, those two MRI studies with similar
cut-off values as in our study identify MPA dilatation
in 76% [4] and 54% of MFS [3] which was similar to
our 69.4%.
We identify MPA aneurysms in 19% of MFS patients.
The single study in the literature that also assesses the
prevalence of MPA aneurysm in MFS reports an even
higher frequency of 4 in 11 adults with MFS (36.4%)
[73]. However, we did not identify any patient who re-
quired surgery for MPA-d >6.0 cm, or with complica-
tions such as regurgitation of the pulmonary valve, MPA
dissection, or upper airway compression. In the series
of Detrano et al. there was a single patient in 11 adults
with MFS who exhibited an MPA-d >6.0 cm (9%) [73].
There is only casuistic evidence for complications of
MPA aneurysm in MFS [49,50,52]. Interestingly, the
Framingham Heart Study noted self-reported dyspnoea
on exertion in 20% of normal persons with MPA-d above
upper normal limits [14]. We did not assess symptoms in
our MFS patients, but in summary there is little evidence
Figure 2 The qnorm (Q-Q plot) plots the quantiles of MPA diameters (cm) of 123 normal adults against the quantiles of a normal
distribution where the pattern of points in the plot is used to compare these two distributions. The plot identifies normal distribution
with only a slight deviation from normality at the upper tail. The Shapiro-Wilk W test for normal data corroborates normal distribution of MPA
diameters yielding W = 0.98330, V = 1.641, z = 1.111, and P = .133.
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tions in MFS.
The Framingham Heart Study defined their normal
cohort of 706 persons similar to our criteria as indi-
viduals without obesity, arterial hypertension, current
and past smokers, chronic obstructive pulmonary dis-
ease, history of pulmonary embolism, diabetics, cardio-
vascular disease, and heart valve surgery [14]. The
study corroborated our finding that body height, body
weight, BMI and BSA were not needed to define nor-
mal upper limits of MPA-d. We also did not identify
significant sex-specific differences of MPA-d, whereas
the Framingham study was the only study to define
cut-off values for women and men. However, their nor-
mal population consisted of men aged >35, and women
aged >40 years [14], whereas our normal population in-
cluded much younger persons of both sexes. Moreover,
studies with similar age distribution as in our study cor-
roborated lack of significant differences between both
sexes [13,19].
Our study defined >1.05 as upper normal limit of
MPA-r on echocardiography, and thus corroborated
thresholds form CT or MRI studies [16-19]. However, it
is important to note that we measured aortic diameters
at the level of the aortic sinuses, whereas MRI studies
obtained aortic diameters as transverse axial diameters
of the ascending aorta. Interestingly, with >0.9 the
Framingham study reported an unusually low upper
normal limit of MPA-r. But again, the Framingham study
included only persons aged >35 years, and MPA-r isknown to decrease with age, because only the proximal
aorta dilates with older age [19]. Because of its age depend-
ency, MPA-r is considered only of limited value for diag-
nosing PH [19].
We found MPA-r >1.05 with similar frequency in nor-
mal persons (5%) and in MFS (10.5%). This finding may
be conceived as “pseudo-normal” MPA-r in MFS, where
dilatation of MPA is neutralized by dilatation of the aor-
tic root. Hence, MPA-r is not a good marker of MPA
dilatation in MFS. However, we found a relationship of
MPA-r with PASP in our MFS patients (regression coef-
ficient (b) = .009; 95% CI .000–.017; P = .047), and hence,
increased MPA-r may be useful to identify PH with in-
creased risk for MPA aneurysm in MFS.
We identified a relationship of MPA dilatation with re-
duced LVEF, dilated LVEDD [74,75] and with increased
PASP in MFS. Hence, MFS patients may develop high-
pressure MPA aneurysm [52] when pulmonary hyperten-
sion develops from decreases of their myocardial function.
Such decreases of myocardial function frequently develop
in MFS from regurgitation of the aortic or mitral valve [76]
or after repeated heart surgery [77,78].
Manifestations of MFS result from weakness of the
tissue. Hence, it appears surprising that MPA-d did not
relate to any other manifestations of MFS such as ecto-
pia lentis, pneumothorax, dural ectasia, striae distensae,
marked myopia, mitral valve prolapse, or Ghent scores of
system involvement. A possible explanation is that add-
itional factors are needed to manifest MPA dilatation. The
association of enlarged MPA-d with increased PASP may
Figure 3 The box-and-whiskers plots of main pulmonary artery
diameters (MPA, upper panel) and of MPA ratios (lower panel).
Both, MPA diameters (P < .001) and MPA ratios (P < .001) were larger
in Marfan syndrome than in normal adults.
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manifest formation of marked MPA aneurysm in MFS.
With FBN1 mutations located in exons 24–32 MFS
exhibits both, more pronounced aortic root disease [71]
and more frequent ventricular arrhythmia events [7].
However, we did not identify a relationship of FBN1 mu-
tation characteristics with increased MPA-d. This find-
ing supports the idea that MPA dilatation is driven by
factors, which may not relate directly of the underlying
disease mechanisms of MFS.
Study limits
Some issues of our study may need discussion for appro-
priate estimation of our findings. First, our study provides
normal echocardiographic values of MPA-d for adults,
which can be used in any clinical setting independently of
MFS. However, larger populations may be needed to
corroborate our normative thresholds. Second, our MFS
patients were sampled retrospectively with selection
for availability of original echocardiographic recordings.Third, echocardiography may not be optimal for measur-
ing MPA-d in adults, because diameters of the arterial
walls are parallel to the direction of the scan plane and
may thus not be measured precisely [27], or measure-
ments may be inadequate as found in 5.3% of our MFS pa-
tients, and in 4% of MFS patients reported by De Backer
et al. [2]. However, a recently published quality review
of echocardiographic measurements found that intra-
observer agreements for aortic root and MPA measure-
ments were excellent [79]. Moreover, we did not include
measurements of the pulmonary root because these were
too variable both between the same observer and between
different observers. Fourth, the levels and techniques of
echocardiographic MPA measurements are not universally
defined and hence our data may not be comparable with
measurements in the literature. Fifth, we estimated PASP
from non-invasive echocardiography without validation
through right-heart catheterization [58]. Finally, our cross-
sectional study was retrospective with reevaluation of rou-
tine echocardiographic examinations, where prospective
longitudinal studies with standardized echocardiographic
protocols may be needed to evolve the natural history of
MPA dilatation in MFS.
Conclusions
We establish 2.6 cm as upper normal value of echocar-
diographic MPA-d and 1.05 for MPA-r. In MFS, the
prevalence of MPA dilatation is 69.4% and the preva-
lence of MPA aneurysm is 15.3%. However, patients may
require MPA surgery only in scarce circumstances, most
likely because formation of marked MPA aneurysm may
require LV dysfunction and increased PASP.
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